187 related articles for article (PubMed ID: 12050534)
1. Re: Diethylstilbesterol revisited: androgen deprivation, osteoporosis an prostate cancer.
Pitts WR
J Urol; 2002 Jul; 168(1):201; author reply 201. PubMed ID: 12050534
[No Abstract] [Full Text] [Related]
2. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
3. Re: Diethylstilbesterol revised: androgen deprivation, osteoporosis and prostate cancer.
Pitts WR
J Urol; 2002 Nov; 168(5):2131-2. PubMed ID: 12394735
[No Abstract] [Full Text] [Related]
4. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
5. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
Cai T; Bartoletti R
J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
[No Abstract] [Full Text] [Related]
6. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer.
Scherr D; Pitts WR; Vaughn ED
J Urol; 2002 Feb; 167(2 Pt 1):535-8. PubMed ID: 11792913
[TBL] [Abstract][Full Text] [Related]
7. Bone loss accompanying medical therapies.
Dawson-Hughes B
N Engl J Med; 2001 Sep; 345(13):989-91. PubMed ID: 11575293
[No Abstract] [Full Text] [Related]
8. Management of treatment-related osteoporosis in men with prostate cancer.
Smith MR
Cancer Treat Rev; 2003 Jun; 29(3):211-8. PubMed ID: 12787715
[TBL] [Abstract][Full Text] [Related]
9. [The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma].
Kliesch S; Behre HM; Roth S
Dtsch Med Wochenschr; 1997 Jul; 122(30):940-5. PubMed ID: 9280708
[No Abstract] [Full Text] [Related]
10. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
[No Abstract] [Full Text] [Related]
12. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
13. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer, osteoporosis and fracture risk.
Allain TJ
Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
[TBL] [Abstract][Full Text] [Related]
15. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
Izumi K; Mizokami A; Namiki M
Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
[TBL] [Abstract][Full Text] [Related]
16. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Pitts WR
J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
[No Abstract] [Full Text] [Related]
17. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
18. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
Dhanapal V; Reeves DJ
J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
[TBL] [Abstract][Full Text] [Related]
19. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
Seidenfeld J; Samson DJ; Hasselblad V; Aronson N; Albertsen PC; Bennett CL; Wilt TJ
Ann Intern Med; 2000 Apr; 132(7):566-77. PubMed ID: 10744594
[TBL] [Abstract][Full Text] [Related]
20. Re: Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer.
Pitts WR
J Urol; 2002 Oct; 168(4 Pt 1):1506-7. PubMed ID: 12352441
[No Abstract] [Full Text] [Related]
[Next] [New Search]
